• Home

Home > Medical Reference > Encyclopedia (English)

Toggle: English / Spanish

Polycythemia vera

• Overview
• Symptoms
• Treatment

Alternative Names:

Primary polycythemia; Polycythemia rubra vera; Myeloproliferative disorder; Erythremia; Splenomegalic polycythemia; Vaquez's disease; Osler's disease; Polycythemia with chronic cyanosis - Myelopathic polycythemia; Erythrocytosis megalosplenica; Cryptogenic polycythemia

Treatment:

The objective of treatment is to reduce the high blood viscosity (thickness of the blood) due to the increased red blood cell mass and to prevent hemorrhage and thrombosis.

Phlebotomy is one method used to reduce the high blood viscosity. In phlebotomy, 1 unit (pint) of blood is removed weekly until the hematocrit is less than 45, then phlebotomy is continued as necessary.

Occasionally, chemotherapy may be given to suppress the bone marrow. Other agents such as interferon may be given to lower blood counts. Anegrelide may be given to lower platelet counts.

The use of anti-platelet therapy (such as aspirin) is controversial because it may cause stomach bleeding.

Allopurinol is given for hyperuricemia ( gout ).

Expectations (prognosis):

Polycythemia vera usually develops slowly, and most patients treated appropriately do not experience any problems related to the disease. However, the abnormal bone marrow cells may begin to grow uncontrollably leading to acute myelogenous leukemia. This occurs in a minority of cases.

Patients with polycythemia vera also have an increased tendency to form blood clots that can result in strokes or heart attacks. Some patients may experience abnormal bleeding because their platelets are abnormal.

Complications:

• Thrombosis (a cause of stroke or heart attack)
• Peptic ulcer disease
• Gastric bleeding
• Gout
• Leukemia
• Heart failure
• Myelofibrosis

Calling your health care provider:

Call your health care provider if symptoms of polycythemia vera develop.

• Review Date: 10/31/2005
• Reviewed By: William Matsui, M.D., Assistant Professor of Oncology, Division of Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD. Review provided by VeriMed Healthcare Network.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process . A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. Copyright 1997-2007 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.